{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:18:13Z","timestamp":1787944693220,"version":"build-2784847793"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Diazoxide is used for persistent or recurrent hypoglycemia when the clinical and biochemical pattern is compatible with hyperinsulinism, but neonatal treatment populations are heterogeneous. We evaluated the clinical and hormonal characteristics and short-term outcomes associated with diazoxide use in hypoglycemic neonates. Methods: This single-center retrospective cohort included 124 hypoglycemic neonates treated between January 2020 and January 2026; 36 received diazoxide and 88 did not. Critical hormonal samples were obtained concurrently with glucose &lt; 47 mg\/dL; in treated infants, sampling preceded the first diazoxide dose. Hormonal effects were estimated with parsimonious multivariable models. Diazoxide-selection factors were examined with a reduced logistic model and Firth sensitivity analysis. Results: Treated infants were more frequently preterm (80.6% vs. 52.3%; p = 0.003) and had greater pre-treatment sepsis and ventilation burden. Severe hypoglycemia &lt; 25 mg\/dL did not differ significantly (27.8% vs. 17.0%; p = 0.176). Insulin was higher with diazoxide (median 6.05 vs. 2.77 mU\/L; adjusted GMR 2.23, 95% CI 1.38\u20133.61; p = 0.001), as was C-peptide (adjusted GMR 1.59, 95% CI 1.03\u20132.47; p = 0.038). Among treated infants, 35\/36 had insulin &gt; 1.25 mU\/L; 17\/29 with available maximum glucose-infusion-rate data required &gt;8 mg\/kg\/min. Diazoxide began at a median postnatal age of 10.5 days; 30\/36 infants remained on therapy at discharge. Fluid retention requiring diuretics occurred in 11\/36 (30.6%) versus 11\/88 (12.5%; p = 0.017). Pulmonary hypertension was not documented on routine day 5\u20137 echocardiography (0\/36; exact 95% CI 0.0\u20139.7%). Conclusions: Diazoxide use identified a clinically vulnerable, treatment-selected subgroup with evidence of inadequate insulin suppression during hypoglycemia. The data do not establish uniformly confirmed hyperinsulinism. Fluid retention was the main documented treatment-period adverse event; rare or later cardiopulmonary complications cannot be excluded by this retrospective cohort.<\/jats:p>","DOI":"10.3390\/children13091157","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:33:52Z","timestamp":1787942032000},"page":"1157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Hormonal Characteristics and Short-Term Outcomes of Diazoxide Use in Hypoglycemic Neonates: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Sevil","family":"Bali","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Haseki Training and Research Hospital, University of Health Sciences, Istanbul 34265, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Burcu","family":"Cebeci","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul 34265, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1542\/peds.2010-3851","article-title":"Postnatal glucose homeostasis in late-preterm and term infants","volume":"127","author":"Adamkin","year":"2011","journal-title":"Pediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","article-title":"Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children","volume":"167","author":"Thornton","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jpeds.2015.02.045","article-title":"Re-evaluating transitional neonatal hypoglycemia: Mechanism and implications for management","volume":"166","author":"Stanley","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000531766","article-title":"International guidelines for the diagnosis and management of hyperinsulinism","volume":"97","author":"Arnoux","year":"2024","journal-title":"Horm. Res. Paediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1787","DOI":"10.1210\/clinem\/dgae267","article-title":"Approach to the neonate with hypoglycemia","volume":"109","author":"Lord","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1504909","article-title":"Neonatal glycemia and neurodevelopmental outcomes at 2 years","volume":"373","author":"McKinlay","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jamapediatrics.2017.1579","article-title":"Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years","volume":"171","author":"McKinlay","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000492859","article-title":"Neonatal glycaemia and neurodevelopmental outcomes: A systematic review and meta-analysis","volume":"115","author":"Shah","year":"2019","journal-title":"Neonatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpeds.2015.09.045","article-title":"Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children","volume":"168","author":"Ferrara","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cen.15137","article-title":"Biomarkers and diagnostic thresholds for congenital hyperinsulinism","volume":"102","author":"Petkovic","year":"2025","journal-title":"Clin. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41372-020-00891-w","article-title":"Prolonged transitional neonatal hypoglycaemia: Characterisation of a clinical syndrome","volume":"41","author":"Bailey","year":"2021","journal-title":"J. Perinatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1210\/clinem\/dgaa543","article-title":"Management and appropriate use of diazoxide in infants and children with hyperinsulinism","volume":"105","author":"Brar","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit","volume":"38","author":"Gray","year":"2018","journal-title":"J. Perinatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Collins, L.C., Daniel, K.B., Tolia, V.N., Parikh, P., Gray, K.D., and Greenberg, R.G. (2026). Prevalence and safety of diazoxide in the neonatal intensive care unit. J. Perinatol., 1\u20137.","DOI":"10.1038\/s41372-026-02568-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/jc.2018-01613","article-title":"Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide","volume":"103","author":"Herrera","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Newman-Lindsay, S., Lakshminrusimha, S., and Sankaran, D. (2023). Diazoxide for neonatal hyperinsulinemic hypoglycemia and pulmonary hypertension. Children, 10.","DOI":"10.3390\/children10010005"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1055\/s-0043-1764385","article-title":"Pulmonary hypertension and necrotizing enterocolitis in neonates treated with diazoxide","volume":"41","author":"Duggal","year":"2024","journal-title":"Am. J. Perinatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00431-019-03544-z","article-title":"Higher C-peptide levels and glucose requirements may identify neonates with transient hyperinsulinism hypoglycemia who will benefit from diazoxide treatment","volume":"179","author":"Haham","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1542\/peds.2008-0806","article-title":"Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency","volume":"122","author":"Kelly","year":"2008","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2415764","DOI":"10.1001\/jamanetworkopen.2024.15764","article-title":"Diazoxide for severe or recurrent neonatal hypoglycemia: A randomized clinical trial","volume":"7","author":"Laing","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apa.14252","article-title":"Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects","volume":"107","author":"Balachandran","year":"2018","journal-title":"Acta Paediatr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/cen.14987","article-title":"Low-dose diazoxide is safe and effective in infants with transient hyperinsulinism","volume":"100","author":"Malhotra","year":"2024","journal-title":"Clin. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chen, X., Feng, L., Yao, H., Yang, L., and Qin, Y. (2021). Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246463"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e20193202","DOI":"10.1542\/peds.2019-3202","article-title":"Necrotizing enterocolitis in neonates with hyperinsulinemic hypoglycemia treated with diazoxide","volume":"147","author":"Keyes","year":"2021","journal-title":"Pediatrics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/archdischild-2020-319057","article-title":"Necrotising enterocolitis in newborns receiving diazoxide","volume":"106","author":"Prado","year":"2021","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_28","first-page":"775","article-title":"Does the use of diazoxide for hyperinsulinaemic hypoglycaemia increase the risk of necrotising enterocolitis in neonates?","volume":"108","author":"Yeung","year":"2023","journal-title":"Arch. Dis. Child."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/9\/1157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:53:35Z","timestamp":1787943215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/9\/1157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["children13091157"],"URL":"https:\/\/doi.org\/10.3390\/children13091157","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}